PH1 Payload Platform Akari's PH1 RNA splicing modulator payload enables the rapid generation of multiple ADC molecules across cancer targets, offering a licenseable or co-development opportunity for pharma partners seeking novel payloads and unique MOA that can synergize with checkpoint inhibitors.

Targeted ADC Programs Lead assets AKTX-101 targeting Trop2 and AKTX-102 targeting CEACAM5 demonstrate a focused, antigen-driven pipeline; this presents opportunities for collaboration or licensing with companies pursuing Trop2- or CEACAM5-directed therapies and want to harness PH1's payload.

CDMO Collaboration Akari's collaboration with WuXi XDC to develop and manufacture ADCs signals a scalable path-to-market, creating a low-friction route for potential partners to advance PH1-based ADCs via established manufacturing capabilities.

Executive Credibility Strategic leadership under CEO Abizer Gaslightwala and an active Scientific Advisory Board (including new member Prafulla Gokhale) combined with major conference presence (ASCO, AACR) enhances credibility for partnering discussions and co-development opportunities.

Growth Readiness With modest revenue and a clear pipeline, Akari presents an attractive partner profile for milestone-driven licensing, upfront payments, and collaboration deals, as it expands its PH1 payload platform and ADC portfolio.